<DOC>
	<DOC>NCT02782845</DOC>
	<brief_summary>This study will assess the prophylactic effect of pegfilgrastim (Neulastim) on febrile and/or Grade IV neutropenia in participants receiving chemotherapy (CT) or immunochemotherapy (ICT) as first or second line treatment for NHL. Pegfilgrastim will be administered at a fixed dose of 6 milligrams (mg) subcutaneously 24 hours after the last dose of CT or ICT in each treatment cycle.</brief_summary>
	<brief_title>An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<criteria>NHL supported by an Immunohistochemical report Eastern Cooperative Oncology Group (ECOG) performance status greater than or equal to (&gt;/=) 2 Total serum bilirubin less than (&lt;) 2 times upper limit of normal (ULN) Absolute neutrophil count (ANC) greater than (&gt;) 2 x10^9 per liter (/L) Bone marrow compromised &gt; 10 percent (%) Any malignant myeloid condition Active infections requiring systemic antiinfectious therapies (antibiotics, antifungal drugs, antiviral drugs) within 72 hours prior to CT or ICT initiation Known hypersensitivity reactions to Escherichia coli derived products Pregnant or nursing participants. Women with childbearing potential should use a safe contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>